市場調查報告書

生物標記的全球市場:各產品、種類、疾病適應症、用途、地區的趨勢分析,競爭市場佔有率及預測(2016年∼2026年)

Global Biomarkers Market, By Product,Type, Disease Indication, Application, By Region ; Trend Analysis, Competitive Market Share & Forecast, 2016-2026

出版商 Blueweave Consulting & Research Private Limited 商品編碼 951543
出版日期 內容資訊 英文 165 Pages
商品交期: 最快1-2個工作天內
價格
生物標記的全球市場:各產品、種類、疾病適應症、用途、地區的趨勢分析,競爭市場佔有率及預測(2016年∼2026年) Global Biomarkers Market, By Product,Type, Disease Indication, Application, By Region ; Trend Analysis, Competitive Market Share & Forecast, 2016-2026
出版日期: 2020年06月01日內容資訊: 英文 165 Pages
簡介

全球生物標記市場,癌症發生率高,及其伴隨的研究努力,促進成長。由於不活躍的生活方式,不健康的伙食,運動不足造成的心血管疾病、癌症、糖尿病等長壽疾病全球性增加,成為促進該市場成長的重要要素。還有成為製藥、生物企業的研究開發的動力和的研究開發費的增加,在新興國家的CRO增加和臨床試驗的低成本化,癌症的多發等也成為該市場的成長要素。同時,高資本節約率和低成本效益率,法規和返還制度不足,樣品群和保管相關的技術問題等,成為抑制該市場成長的重要要素。

本報告提供全球生物標記市場的相關調查,市場機會和課題,成長及阻礙因素,各產品、類型、疾病適應症、用途、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 調查架構

第2章 調查手法

第3章 摘要整理

第4章 產業考察

  • 產業的價值鏈分析
  • DROC分析
    • 成長要素
    • 阻礙因素
    • 市場機會
    • 課題
  • 技術形勢/最近的開發
  • 法律規範
  • 企業的市場佔有率分析(2019)
  • 波特的五力分析
  • COVID-19的影響

第5章 全球生物標記市場概要

  • 市場估計及預測:各銷售額
  • 市場佔有率及預測
    • 各產品
      • 消耗品
      • 服務
    • 各類型
      • 安全性
      • 功效
      • 檢驗
    • 各疾病適應症
      • 癌症
      • 心血管疾病
    • 各用途
      • 診劃分發
      • 藥物研發與開發
      • 病的風險
    • 各地區
      • 北美
      • 歐洲
      • 亞太地區
      • 南美
      • 中東、非洲

第6章 北美市場

第7章 歐洲市場

第8章 亞太地區市場

第9章 南美市場

第10章 中東、非洲市場

第11章 企業簡介(企業概要,財務矩陣,主要產品的展望,主要員工,主要的競爭,聯絡原住所,策略性預測)

  • Qiagen N.V.
  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-La Roche Ltd,
  • PerkinElmer Inc.,
  • Merck KGaA,
  • Bio-Rad Laboratories,
  • Abbott Laboratories,
  • EKF Diagnostics
  • Enzo Biochem Inc.
  • Meso Scale Diagnostics, LLC
  • Signosis,
目錄
Product Code: BWC20076

Biomarkers are widely used in the analysis and management of multiple diseases. Physiological levels of biomarkers also change upon the administration of drugs. The study of numerous biomarkers helps clinicians make meaningful choices about the analysis, disease stage, therapy plan, and prognosis in patients.

The high occurrence of cancer is inspiring research initiatives, motivating the development of the market. Extensive research and technological advancements used for the development of biomarker-based clinical diagnostics are predictable to be the key funders for exchange. An increase in the global affliction of long-lasting diseases, particularly cardiovascular, cancer, diabetes disorders due to an inactive lifestyle, unhealthy diet, and lack of exercise, has been a significant factor motivating the market growth. Increasing R&D fueling for pharma and biotech companies, a growing number of CROs and low cost of clinical trials in emerging countries, the high occurrence of cancer, and new edges for research. On the other hand, high capital savings and low cost-benefit ratio poorly suited regulatory and repayment systems, and technical issues related to sample group and storage are the significant reasons confining the growth of this market.

The request for diagnostic markets is growing. Where unoriginal diagnostic tools were focused on making accurate and reliable results, today's market request extends to new analysis with actual and steady results. There are essential challenges in presenting accurate results in the early stage of diseases, especially in the case of cancer.

Investigative biomarkers are negligible or non-invasive tools. Biomarkers, combined with crucial imaging and data management technologies, are meeting the market prospects; however, they have setbacks too. Biomarkers are used in imaging technology to deliver precise imaging of oncology tumors and other problems and remove the chance of energy revelation during imaging through CT scan and MRI scan.

Growth Drivers

Increasing usage of biomarkers in cancer treatment is driving the market growth.

Biomarkers are used in application areas such as companion diagnostics, personalized medicines, and other diagnostic areas, including drug discovery and growth and disease risk assessment. These growing diagnostic uses of biomarkers are predictable to drive market growth in the coming years. Companion diagnostics and biomarkers have become progressively pertinent in the practice of medicine, foremost to improved diagnosis, dealing, and monitoring across several disease areas. It can be used to recognize patients likely to reply well to certain drugs or cure options. These diagnostics are often used in combination with a specific drug.

Technological Advancement

Technological advancements have permitted the grouping of biomarkers with novel drugs for precise diagnosis and following cure options. For instance, biomarkers can be functional for the cure of several neurological diseases by stalking brain health and activity by examining biomolecules. Nascent developments, such as biomarker signatures, have augmented the treatment rate of nervous disorders resulting in early diagnosis, non-invasive testing, and rapid drug development.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary & Secondary Sources
  • 2.2. Quantitative Research
    • 2.2.1. Primary & Secondary Sources
  • 2.3. Market Breakdown & Data Triangulation
    • 2.3.1. Secondary Research
    • 2.3.2. Primary Research
  • 2.4. Breakdown of Primary research respondent, By Region
  • 2.5. Assumption & Limitation

3. Executive Summary

4. Global Biomarker market Industry Insights

  • 4.1. Industry Value Chain Analysis
  • 4.2. DROC Analysis
    • 4.2.1. Growth Drivers
    • 4.2.2. Restraint
    • 4.2.3. Opportunities
    • 4.2.4. Challenges
  • 4.3. Technological Landscape/Recent Development
  • 4.4. Regulatory Framework
  • 4.5. Company Market Share Analysis, 2019
  • 4.6. Porter's Five Forces Analysis
    • 4.6.1. Bargaining Power of Suppliers
    • 4.6.2. Bargaining Power of Buyers
    • 4.6.3. Threat of New Entrants
    • 4.6.4. Threat of Substitutes
    • 4.6.5. Intensity of Rivalry
  • 4.7. Impact of COVID 19

5. Global Biomarker market Overview

  • 5.1. Market Size & Forecast by Value, 2016-2026
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product
      • 5.2.1.1. Consumables
      • 5.2.1.2. Service
    • 5.2.2. By Type
      • 5.2.2.1. Safety
      • 5.2.2.2. Efficacy
      • 5.2.2.3. Validation
    • 5.2.3. By Disease Indication
      • 5.2.3.1. Cancer
      • 5.2.3.2. Cardiovascular Disorders
    • 5.2.4. By Application
      • 5.2.4.1. Diagnostics Development
      • 5.2.4.2. Drug Discovery and Development
      • 5.2.4.3. Disease-Risk
    • 5.2.5. By Region
      • 5.2.5.1. North America
      • 5.2.5.2. Europe
      • 5.2.5.3. Asia Pacific
      • 5.2.5.4. Latin America
      • 5.2.5.5. Middle East & Africa

6. North America Biomarker Market

  • 6.1. Market Size & Forecast by Value, 2016-2026
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Type
    • 6.2.3. By Disease Indication
    • 6.2.4. By Application
    • 6.2.5. By Country
      • 6.2.5.1. United States
      • 6.2.5.2. Canada

7. Europe Biomarker market

  • 7.1. Market Size & Forecast by Value, 2016-2026
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Type
    • 7.2.3. By Disease Indication
    • 7.2.4. By Application
    • 7.2.5. By Country
      • 7.2.5.1. Germany
      • 7.2.5.2. United Kingdom
      • 7.2.5.3. France
      • 7.2.5.4. Italy
      • 7.2.5.5. Spain
      • 7.2.5.6. Rest of Europe

8. Asia Pacific Biomarker Market

  • 8.1. Market Size & Forecast by Value, 2016-2026
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Type
    • 8.2.3. By Disease Indication
    • 8.2.4. By Application
    • 8.2.5. By Country
      • 8.2.5.1. India
      • 8.2.5.2. China
      • 8.2.5.3. Japan
      • 8.2.5.4. South Korea
      • 8.2.5.5. Rest of Asia Pacific

9. Latin America Biomarker Market

  • 9.1. Market Size & Forecast by Value, 2016-2026
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
      • 9.2.1.1. By Product
      • 9.2.1.2. By Type
      • 9.2.1.3. By Disease Indication
      • 9.2.1.4. By Application
      • 9.2.1.5. By Country
      • 9.2.1.5.1. Brazil
      • 9.2.1.5.2. Mexico
      • 9.2.1.5.3. Rest of Latin America

10. Middle East & Africa Biomarker Market

  • 10.1. Market Size & Forecast by Value, 2016-2026
    • 10.1.1. By Value (USD Million)
  • 10.2. Market Share & Forecast
      • 10.2.1.1. By Product
      • 10.2.1.2. By Type
      • 10.2.1.3. By Disease Indication
      • 10.2.1.4. By Application
      • 10.2.1.5. By Country
      • 10.2.1.5.1. Saudi Arabia
      • 10.2.1.5.2. UAE
      • 10.2.1.5.3. South Africa
      • 10.2.1.5.4. Rest of Middle East & Africa

11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *

  • 11.1. Qiagen N.V.
  • 11.2. Thermo Fisher Scientific Inc.
  • 11.3. F. Hoffmann-La Roche Ltd,
  • 11.4. PerkinElmer Inc.,
  • 11.5. Merck KGaA,
  • 11.6. Bio-Rad Laboratories,
  • 11.7. Abbott Laboratories,
  • 11.8. EKF Diagnostics
  • 11.9. Enzo Biochem Inc.
  • 11.10. Meso Scale Diagnostics, LLC
  • 11.11. Signosis,
  • 11.12. Other Prominent Players

* Financial details in case of unlisted companies will be available as per data availability

**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable.